Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 13/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22092078 | 0.94 | FGFR3 (0.42) | GPR139FGFR3KDRACACBHAO1 | |
| SCHEMBL22092043 | 0.86 | FGFR3 (0.43) | GPR139FGFR3KDRACACBHAO1 | |
| SCHEMBL22092244 | 0.82 | FGFR3 (0.41) | GPR139FGFR3KDRACACB | |
| SCHEMBL22092076 | 0.81 | GPR139 (0.37) | GPR139 | |
| SCHEMBL30641014 | 0.81 | GPR139 (0.37) | GPR139 | |
| SCHEMBL22206347 | 0.80 | GPR139 (0.34) | GPR139HTR1ADRD2HTR2AGRM5 | |
| SCHEMBL22206346 | 0.78 | GPR139 (0.35) | GPR139 | |
| SCHEMBL30641018 | 0.78 | GPR139 (0.35) | GPR139 | |
| SCHEMBL22206390 | 0.78 | GRM5 (0.45) | GPR139GRM5 | |
| SCHEMBL22092121 | 0.78 | GPR139 (0.34) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | claimed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | claimed |
| EP-3894408-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2021-10-20 | — | — | EP | claimed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | claimed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | claimed |
| WO-2020121263-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-06-18 | — | — | WO | claimed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | disclosed |
| EP-3894408-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2021-10-20 | — | — | EP | disclosed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| WO-2020121263-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885FGFR3 3896/4885KDR 3046/4885 |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885FGFR3 3896/4885KDR 3046/4885 |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885FGFR3 3896/4885KDR 3046/4885 |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885FGFR3 3896/4885KDR 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.